

Curriculum vitae

INFORMAZIONI PERSONALI De Giglio Andrea

✉ andrea.degiglio2@unibo.it

Sesso Maschile | Data di nascita 28/05/1989 | Nazionalità Italiana

Stato civile Convivente, 1 figlio

Il sottoscritto De Giglio Andrea,

è consapevole delle responsabilità penali e degli effetti amministrativi derivanti dalla falsità in atti e dalle dichiarazioni mendaci (così come previsto dagli artt. 75 e 76 del D.P.R. n. 445 del 28.12.2000), ai sensi e per gli effetti di cui agli artt. 46 e 47 del medesimo D.P.R. n. 445 del 28.12.2000

Il sottoscritto, sotto la sua personale responsabilità, dichiara di essere in possesso delle sottoindicate esperienze formative e professionali:

ESPERIENZA PROFESSIONALE

- 20/02/2023-presente **Ricercatore a tempo determinato Cat. A**
Dipartimento di Scienze Mediche e Chirurgiche
Università degli Studi di Bologna
U.O.C. Oncologia Medica- IRCCS Sant'Orsola-Malpighi, Bologna
- 16/11/2020-19/02/2023 **Assegno di ricerca**
Dipartimento Medicina Specialistica, Diagnostica e Strumentale
Università degli Studi di Bologna
U.O.C. Oncologia Medica- IRCCS Sant'Orsola-Malpighi, Bologna
- 01/02/2021-31/08/2021 **Contratto Libero Professionale Emergenza Sanitaria Covid (det. N. 51 del 28/01/2021)**
U.O.C. Oncologia Medica- IRCCS Sant'Orsola-Malpighi, Bologna
- 01/12/2020-31/03/2021 **Contratto Libero Professionale**
Dipartimento Medicina Specialistica, Diagnostica e Strumentale
Università degli Studi di Bologna
U.O.C. Oncologia Medica- IRCCS Sant'Orsola-Malpighi, Bologna
Progetto: "Attività di raccolta e analisi dati nell'ambito dello studio per la valutazione di PD-L1 e di altri marcatori predittivi di efficacia per l'immunoterapia e di Cellule Tumoralì Circolanti in pazienti con Carcinoma del Polmone Non a Piccole Cellule". Rep. n. 9356/2020 Prot. n. 282807 del 26/11/2020.
- 01/12/2017-31/12/2017
01/12/2018-31/12/2018 **Medico di Continuità Assistenziale**
A.S.L. Umbria 1 - Distretto Alto Chiascio
- 01/07/2014-31/10/2015 **Medico di Continuità Assistenziale**
A.S.L. di Reggio Emilia, Correggio (Italia)
- 01/10/2011-01/10/2013 **Tutor universitario**
Università degli Studi di Parma, Parma (Italia)
Attività di tutoraggio per studenti iscritti al corso di laurea in Medicina e Chirurgia

ISTRUZIONE E FORMAZIONE

01/11/2020-presente **Dottorato in Oncologia, Ematologia e Patologia**

Curriculum vitae

Università degli Studi di Bologna, Bologna (Italia)

Titolo Progetto: Fattori prognostici e predittivi di risposta alle terapie a bersaglio molecolare ed immunoterapia nel cancro del polmone

01/11/2015–11/11/2020

Scuola di Specializzazione in Oncologia Medica (110/110 cum laude)

Università degli Studi di Bologna, Bologna (Italia) (01/11/19-11/11/20)

Università degli studi di Perugia, Perugia (Italia) (01/11/15-31/10/19)

Tesi di specializzazione: Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI).

11/02/2014–presente

Abilitazione professionale

Università degli Studi di Parma, Parma (Italia)

01/10/2007–24/10/2013

Laurea Magistrale in Medicina e Chirurgia (110/110 cum laude)

Università degli Studi di Parma, Parma (Italia)

11/09/2002–12/07/2007

Maturità Classica (100/100)

Liceo Classico Quinto Ennio, Taranto (Italia)

Attività di formazione o di ricerca presso Istituti italiani e stranieri qualificati

01/03/2019–31/08/2019

Institut Gustave Roussy, Villejuif (Francia)

Dipartimento di Oncologia Toracica

Tutors: Dr. David Planchard , Prof. Benjamin Besse

16/11/2020-19/02/2023

**Dipartimento Medicina Specialistica, Diagnostica e Strumentale
Università degli Studi di Bologna**

Progetto assegno di ricerca: Analisi di variazioni di sottopopolazioni leucocitarie e di citochine indotte dall'assunzione di steroidi in corso di immunoterapia per il tumore del polmone non a piccole cellule avanzato

Tutor: Prof. A. Ardizzoni

COMPETENZE PERSONALI

Lingua madre italiano

Lingue straniere

	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
inglese	C1	C1	C1	C1	C1
Malta Magister Academy- Upper Intermediate English Course					
francese	C2	C2	B2	B2	B2
Online Linguistic Support-Erasmus Plus					

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato
Quadro Comune Europeo di Riferimento delle Lingue

Competenze informatiche R-Studio, SPSS, Mendeley, Zotero, Review Manager, CBioPortal, Pacchetto Office

PUBBLICAZIONI SCIENTIFICHE
(SCOPUS H-INDEX: 19, CITAZIONI: 1323)

Totale: 61 pubblicazioni in extenso, di cui 20 come primo/ultimo nome, 3 come corresponding author.

- 1 Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient.
Ricciuti B, Leonardi GC, Ravaoli N, et al.
J Breast Cancer. 2016 Sep;19(3):324-329 **IF 2.204**

- 2 Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?
Ricciuti B, Brambilla M, De Giglio A, et al.
Radiat Oncol (2017) 6: 11. <https://doi.org/10.1007/s13566-017-0293-8> **IF 2.862**

- 3 Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy.
Ricciuti B, Baglivo S, Paglialunga L, et al.
Ther Adv Med Oncol. 2017 9(7):1-17 **IF 6.540**

- 4 Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?
De Giglio A, Porreca R, Brambilla M, et al.
Thromb Res. 2017 Dec 9;163:51-53. doi: 10.1016/j.thromres.2017.12.004. **IF 2.952**

- 5 Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
Ricciuti B, De Giglio A, Mecca C, et al.
Med Oncol. 2018 Apr 17;35(5):72. doi: 10.1007/s12032-018-1133-4 **IF 3.252**

- 6 Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation
Baglivo S, Ricciuti B, Ludovini V, et al.
Journal of Thoracic Oncology Volume 13, Issue 8, August 2018, Pages e145-e147 **IF 12.460**

- 7 Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.
Ricciuti B, Baglivo S, De Giglio A, et al.
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618808659. doi: 10.1177/1753466618808659.
IF 3.18

- 8 Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B, Genova C, De Giglio A, et al.
J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. **IF 3.656**

- 9 A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
Cortellini A, Bersanelli M, Buti S, et al.
C. J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y. **IF 10.252**

Curriculum vitae

- 10 Safety and efficacy of nivolumab in patients with advanced non-small cell lung cancer treated beyond progression.
Ricciuti B, Genova C, Bassanelli M, et al.
Clin Lung Cancer. 2019 May;20(3):178-185.e2. doi:10.1016/j.clcc.2019.02.001. **IF 3.550**
- 11 Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni , Carteni G, Cortesi E, et al.
J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z. **IF 10.252**
- 12 Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
Abu-Sbeih H, Ali FS, Naqash AR, et al.
Journal of Clinical Oncology. 2019 Jun 4;:JCO1900320. doi: 10.1200/JCO.19.00320. **IF 32.956**
- 13 Primary Angiosarcoma of the Kidney: Case Report and Comprehensive Literature Review.
Boni A, Cochetti G, Sidoni A, et al.
Open Med (Wars). 2019 Jul 31;14:443-455. doi: 10.1515/med-2019-0048. eCollection 2019. **IF 1.204**
- 14 Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
Ricciuti B, Brambilla M, Cortellini A, et al.
Clin Transl Oncol. 2019 Jul 22. doi: 10.1007/s12094-019-02175-y. **IF 2.737**
- 15 Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Cortellini A, Leonetti A, Catino A, et al.
Clin Transl Oncol. 2019 Aug 7. doi: 10.1007/s12094-019-02193-w. **IF 2.737**
- 16 Antibody–Drug Conjugates for Lung Cancer in the Era of Personalized Oncology.
Ricciuti, B.; Lamberti, G.; Andrini, E., et al.
Seminars in Cancer Biology 2019. <https://doi.org/10.1016/j.semcancer.2019.12.024>. **IF 11.090**
- 17 Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies.
De Giglio A, Nuvola G, Dall'Olio FG.
Translational Cancer Research. 2019;8(8):E18-E23-E23. doi:10.21037/tcr.2019.12.69 **IF 0.949**
- 18 Outcomes Associated with Immune-Related Adverse Events in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab: A Pooled Exploratory Analysis from a Global Cohort.
Naqash, A. R.; Ricciuti, B.; Owen, D. H. et al.
Cancer Immunol Immunother 2020. <https://doi.org/10.1007/s00262-020-02536-5>. **IF 6.968**
- 19 Another Side of the Association between Body Mass Index (BMI) and Clinical Outcomes of Cancer Patients Receiving Programmed Cell Death Protein-1 (PD-1)/ Programmed Cell Death-Ligand 1 (PD-L1) Checkpoint Inhibitors: A Multicentre Analysis of Immune-Related Adverse Events.
Cortellini, A.; Bersanelli, M.; Santini, et al.
European Journal of Cancer 2020, 128, 17–26. <https://doi.org/10.1016/j.ejca.2019.12.031>. **IF 9.162**
- 20 Treatment Patterns and Clinical Outcomes among Patients with ROS1-Rearranged Non-Small Cell

Curriculum vitae

- Lung Cancer Progressing on Crizotinib.
De Giglio A, Lamberti, G.; Facchinetti, F., et al.
Clinical Lung Cancer 2020 <https://doi.org/10.1016/j.clcc.2020.03.008>. IF 3.550
- 21 Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: age, Eastern Cooperative Organization performance status 2, steroids and antibiotics
De Giglio A, Nuvola G, Baldini C.
Future Oncol. 2020;10.2217/fo-2020-0183. doi:10.2217/fo-2020-0183 IF 3.404
- 22 Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Nigro O, Pinotti G, De Galitiis F, et al.
Eur J Cancer. 2020;134:19-28. doi:10.1016/j.ejca.2020.04.025 IF 9.162
- 23 Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience.
Dall'Olio FG, Conci N, Rossi G, et al.
Lung Cancer. 2020;149(August):5-9. doi:10.1016/j.lungcan.2020.08.008 IF 5.705
- 24 Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nslc) patients under immune-checkpoint inhibitors (ICI).
De Giglio A, Mezquita L, Auclin E, et al.
Cancers (Basel). 2020;12(10):1-11. doi:10.3390/cancers12102827 IF 6.126
- 25 Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors
Tateo V, Manuzzi L, De Giglio A, et al.
Int J Mol Sci. 2020;21(23):1-16. doi:10.3390/ijms21239056 IF 5.923
- 26 Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma : A challenging case enhances the need for a multidisciplinary approach
De Giglio A, Scorsetti M, Franceschini D et al.
Eur J Cancer. 2021;143:75-77. doi:10.1016/j.ejca.2020.10.024 IF 9.162
- 27 Smoking status during first - line immunotherapy and chemotherapy in NSCLC patients: A case - control matched analysis from a large multicenter study.
Cortellini*, A, De Giglio*, A, Cannita, K, et al.
Thoracic Cancer. 2021; 12: 880 - 889. <https://doi.org/10.1111/1759-7714.13852> IF 3.223
***these authors equally contributed**
- 28 PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Dall'Olio FG, Gelsomino F, Conci N et al.
Clin Lung Cancer. 2021 Mar 16:S1525-7304(21)00057-7. doi: 10.1016/j.clcc.2021.03.005 IF 3.550
- 29 The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 \geq 50% advanced non-small-cell lung cancer.
Banna GL, Cortellini A, Cortinvis DL, et al.
ESMO Open. 2021;6(2):100078. doi:10.1016/j.esmoop.2021.100078 IF 5.329
- 30 PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for

Curriculum vitae

- advanced NSCLC with PD-L1 expression \geq 50%: Selecting the best strategy.
Di Federico A, De Giglio A, Parisi C, Gelsomino F, Ardizzoni A.
Crit Rev Oncol Hematol. 2021;160:103302. doi:10.1016/j.critrevonc.2021.103302 **IF 5.833**
- 31 IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
Di Federico A, Nuvola G, Deiana C, Donati G, De Giglio A.
J Thorac Oncol. 2021 May;16(5):e29-e30. doi: 10.1016/j.jtho.2021.01.003. **IF 13.357**
- 32 An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances.
Tateo V, Manuzzi L, Parisi C, De Giglio A* et al.
Pharmaceuticals (Basel). 2021;14(4):316. Published 2021 Apr 1. doi:10.3390/ph14040316 **IF 4.286**
***corresponding author**
- 33 PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis
Di Federico A, De Giglio A, Nuvola G, et al.
Future Oncology. 2021. <https://doi.org/10.2217/fon-2021-0328> **IF 2.660**
- 34 PD-1 inhibitors versus PD-L1 inhibitors in addition to chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis
Di Federico A, De Giglio A*, Parisi C, et al.
JTO Clinical and Research Reports. 2021. doi: 10.1016/j.jtocrr.2021.100214.
***corresponding author**
- 35 The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
De Giglio A, Di Federico A, Nuvola G., et al.
Current Oncology Reports. 2021. doi: 10.1007/s11912-021-01124-9. **IF 5.075**
- 36 Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database.
De Giglio A, Di Federico A, Gelsomino F., et al.
Lung Cancer. 2021 Sep 2;161:18-25. doi: 10.1016/j.lungcan.2021.08.017. **IF 5.705**
- 37 STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A, De Giglio A, Parisi C et al.
Eur J Cancer. 2021 Sep 6;157:108-113. doi: 10.1016/j.ejca.2021.08.011. **IF 9.162**
- 38 Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials.
Di Federico A, Rizzo A, Carloni R, et al.
Expert Opin Investig Drugs. 2021;1-9. doi:10.1080/13543784.2022.2009455 **IF 6.206**
- 39 Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Sisi M, Fusaroli M, De Giglio A, et al.
Target Oncol. 2022;17(1):43-51. doi:10.1007/s11523-021-00865-8 **IF 4.493**
- 40 Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities

Curriculum vitae

- De Giglio A, Orlando V, Andriani E, et al.
Tumori. 2022;3008916211069412. doi:10.1177/03008916211069412 **IF 2.098**
- 41 EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.
Di Federico A, Filetti M, Palladini A, et al.
Transl Lung Cancer Res 2022. doi: 10.21037/tlcr-21-888 **IF 6.498**
- 42 Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Riudavets M, Auclin E, Mosteiro M, et al.
Eur J Cancer. 2022;167:142-148. doi:10.1016/j.ejca.2022.02.014 **IF 10.002**
- 43 Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.
Di Federico A, Mosca M, Pagani R, et al.
Cancers (Basel). 2022;14(10):2429. Published 2022 May 14. doi:10.3390/cancers14102429 **IF 6.639**
- 44 Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients
De Giglio A, Deiana C, Di Federico A.
J Cancer Res Clin Oncol. 2022;10.1007/s00432-022-04120-z. **IF 4.553**
- 45 Advanced non-small-cell lung cancer: how to manage non-oncogene disease.
De Giglio A, Di Federico A, Deiana C, et al.
Drugs Context. 2022;11:2022-2-4. <https://doi.org/10.7573/dic.2022-2-4> **IF 5.688**
- 46 Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
Di Federico A, De Giglio A, Gelsomino F, et al.
Cancers. 2022; 14(14):3472. <https://doi.org/10.3390/cancers14143472> **IF 6.575**
- 47 Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
Metro G., De Giglio A*, Ricciuti B, et al.
Drugs Context. 2022;11:2022-3-9. <https://doi.org/10.7573/dic.2022-3-9> **IF 5.688**
***corresponding author**
- 48 Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
De Giglio A, Aprile M, Di Federico A, et al.
International Journal of Molecular Sciences. 2022; 23(18):10292.
<https://doi.org/10.3390/ijms231810292> **IF 6.208**
- 49 Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
De Giglio A, Di Federico A, Metro G.
Transl Lung Cancer Res 2022. doi: 10.21037/tlcr-22-492 **IF 4.726**
- 50 Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis
Di Federico A, De Giglio A, Gelsomino F, et al.

Curriculum vitae

J Natl Cancer Inst. 2022;djac205. doi:10.1093/jnci/djac205 **IF 11.577**

- 51 Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience
De Giglio A, Grandinetti V, Aprile M, et al.
Lung Cancer. 2022 Nov . <https://doi.org/10.1016/j.lungcan.2022.10.007> **IF 6.081**
- 52 Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies
Andrini E, Di Federico A, Sisi M, et al.
Immunotherapy, Nov 2022, <https://doi.org/10.2217/imt-2022-0060> **IF 4.040**
- 53 How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Ricciuti B, Mira A, Andrini E, et al.
Drugs Context. 2022;11:2022-7-4. <https://doi.org/10.7573/dic.2022-7-4> **IF 5.688**
- 54 Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
De Giglio A, Tassinari E, Zappi A et al.
Cancers (Basel). 2022;14(23):5845. Published 2022 Nov 27. doi:10.3390/cancers14235845 **IF 6.575**
- 55 Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive
Nigro MC, Marchese PV, Deiana C, Casadio C, Galvani L, Di Federico A, De Giglio A
Lung Cancer (Auckl). 2023;14:11-25. Published 2023 Feb 3. doi:10.2147/LCTT.S388047 **IF 4.067**
- 56 Peripheral nervous system adverse events associated with immune checkpoint inhibitors
Rossi S, Gelsomino F, Rinaldi R, et al.
J Neurol. 2023;10.1007/s00415-023-11625-1. doi:10.1007/s00415-023-11625-1 **IF 6.174**
- 57 The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks.
De Giglio A, Ricciuti B, Metro G.
Drugs Context. 2023;12:2022-11-4. Published 2023 May 2. doi:10.7573/dic.2022-11-4 **IF 5.688**
- 58 Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant Osimertinib
Di Federico A, De Giglio A, Sperandi F et al.
Anticancer Drugs. 2023; doi:10.1097/CAD.000000000000152 **IF 2.27**
- 59 First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
Mosca M, Nicole C, Di Federico A, Tateo V, Favorito V, Zappi A, Gelsomino F, De Giglio A
JCO Precis Oncol. 2023;7:e2300073. doi:10.1200/PO.23.00073 **IF 5.479**
- 60 Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Raschi E, Rossi S, De Giglio A, et al.
Drug Saf. 2023;10.1007/s40264-023-01320-5. **IF 5.228**
- 61 Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Di Federico A, Ricciotti I, Favorito V, et al.
Curr Oncol Rep. 2023;10.1007/s11912-023-01436-y **IF 5.945**
- Pubblicazioni (abstract) Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels
B Ricciuti, R Chiari, F R Tofanetti, A De Giglio, et al.
Annals of Oncology, Volume 28, Issue suppl_6, 1 October 2017, <https://doi.org/10.1093/annonc/mdx426.013>

Curriculum vitae

- Pubblicazioni (abstract)** Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.
B Ricciuti, A De Giglio, M Brambilla, et al.
Journal of Clinical Oncology 36, 2018 (suppl; abstr 9084)
- Pubblicazioni (abstract)** Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors
M Bassanelli, D Giannarelli, B Ricciuti, et al.
J Clin Oncol 36, 2018 (suppl; abstr e15158)
- Pubblicazioni (abstract)** Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration.
AR Naqash, DH Owen, B Ricciuti, et al.
- Pubblicazioni (abstract)** P1.15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience
M. Bassanelli, D. Giannarelli, B. Ricciuti, et al.
Journal of Thoracic Oncology , Volume 13 , Issue 10 , S611
- Pubblicazioni (abstract)** MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
B. Ricciuti, C. Genova, A. De Giglio, et al.
Journal of Thoracic Oncology , Volume 13 , Issue 10 , S390 - S391
- Pubblicazioni (abstract)** D26 Diagnostic and therapeutic challenges in the management of advanced non-small cell lung cancer among Italian medical oncologists: a national survey
De Giglio A, Orlando V, Lamberti G, et al.
Tumori Journal 2019, Vol. 105(6S) 1– 216
- Pubblicazioni (abstract)** Incidence and Clinical Implications of Late Immune-Related Adverse Events in Long Responders to PD-1/PD-L1 Checkpoint Inhibitors: A Multicenter Study.
Nigro, O.; Cortellini, A.; Giusti, R.; et al.
Annals of Oncology 2019, 30, xi20. <https://doi.org/10.1093/annonc/mdz449.009>.
- Pubblicazioni (abstract)** MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC
Riudavets M, Mezquita L, Auclin E, et al.
Journal of Thoracic Oncology, 2021, 16(3):S161, doi: 10.1016/j.jtho.2021.01.191
- Pubblicazioni (abstract)** P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients
Riudavets M, Auclin E, Blanc-Durand F, et al.
Journal of Thoracic Oncology, 2021, 16(3):S409, doi: 10.1016/j.jtho.2021.01.679
- Pubblicazioni (abstract)** The prognostic role of body-mass index (BMI) for advanced EGFR positive non-small cell lung cancer (NSCLC) patients treated with osimertinib.
De Giglio A, Di Federico A, Donati G, et al.
Journal of Clinical Oncology, 2021, 39(15_suppl):e21078-e21078.
doi: 10.1200/JCO.2021.39.15_suppl.e21078
- Pubblicazioni (abstract)** 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation

Curriculum vitae

outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

Riudavets M, Auclin E, et al.

Annals of Oncology, 2021, DOI: 10.1016/j.annonc.2021.10.041

Pubblicazioni (abstract) 800 Clinicopathological and molecular predictive factors of survival in non-small cell lung cancer patients treated with first-line immunotherapy with or without chemotherapy: a systematic review and meta-analysis

Di Federico A, Gelsomino F, De Giglio A, et al.

JITC , SITC annual meeting, DOI: 10.1136/jitc-2022-SITC2022.0800

Pubblicazioni (abstract) The lung-immune prognostic index (LIPI) to predict early mortality among patients affected by advanced solid cancers under immune-checkpoint inhibitors treatments

De Giglio A, Filippini DM, Mollica V et al.

J Clin Oncol 41, 2023 (suppl 16; abstr e14602), ASCO 2023, 10.1200/JCO.2023.41.16_suppl.e14602

Pubblicazioni (abstract+mini oral presentation) Esmo Immuno Oncology Congress 2019-Mini Oral presentation
46O-Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated

A. De Giglio, L. Mezquita , E. Auclin , et al.

Annals of Oncology (2019) 30 (suppl_11): xi16-xi32. 10.1093/annonc/mdz449

CORSI / CERTIFICAZIONI / Riconoscimenti nazionali

Corsi Corso di Ecografia internistica nel setting di Emergenza-Urgenza
SIMEU (Società italiana medicina emergenza-urgenza)

Corsi Progetto di formazione per la produzione di revisioni sistematiche della letteratura secondo il metodo GRADE per lo sviluppo di raccomandazioni cliniche e linee guida. (21-22/02/2022)
Corso AIOM – Webinar

Corsi Seminario GOIRC per giovani ricercatori (14-15/10/2022)
Università degli Studi di Parma
Elaborazione Progetto: 'A multicenter, open-label, phase II trial investigating the activity of Pembrolizumab combined with histology-driven platinum-based doublets for the treatment of advanced NSCLC progressing during or after durvalumab for locally advanced disease - POST IT TRIAL'

Corsi Progetto di formazione per la produzione di revisioni sistematiche della letteratura secondo il metodo GRADE per lo sviluppo di raccomandazioni cliniche e linee guida. (12-14/06/2023)
Corso AIOM - Roma

Riconoscimenti Premio come miglior poster per il XXXVI Ciclo del Dottorato di Ricerca in Oncologia, Ematologia e Patologia (30/09/2022), Università di Bologna.
Titolo poster: Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

Riconoscimenti Premio fondazione Federico Calabresi Onlus
Congresso Grandangolo in Oncologia (15-16/12/2022)
Pubblicazione premiata: Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC). De Giglio A, et al.
International Journal of Molecular Sciences (2022)

CORSI / CERTIFICAZIONI / Riconoscimenti internazionali

Curriculum vitae

Corsi	ESMO Preceptorship on Immuno-Oncology (04-05/05/2018)
Certificazioni	BIOL-295x: BioStatistics (11/07/2020) Doane University (NE, USA) ID 9a3aa1ac49774e01a27a26997fbe4ca5
Certificazioni	ESMO Examination Certificate (Barcellona, 28/09/2019)
Certificazioni	Advanced cardiovascular life support (ACLS) provider (15/02/2023)
Riconoscimenti	46O-Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated A. De Giglio, L. Mezquita , E. Auclin , et al. Selected for mini-oral presentation at ESMO Immuno-oncology congress (12/12/2019)
Incarico	French Ministry of Health and the National Cancer Institute of France (INCa) Nominato esperto per la revisione di progetti nell'ambito del Translational Cancer Research Programme – PRTK 2022-2023

ATTIVITA' EDITORIALE

Associate Editor	Frontiers in Oncology Section 'Thoracic Oncology' https://loop.frontiersin.org/people/1004703/overview
Guest Editor	Drugs in Context Special issue 'Treatment of advanced non-small-cell lung cancer: one size does not fit all ' https://www.drugsincontext.com/special_issues/treatment-of-advanced-non-small-cell-lung-cancer-one-size-does-not-fit-all/
Guest Editor	Diagnostics Special Issue "Genomic Approach for Diagnosis, Prognosis and Therapy Prediction in Cancer Research" https://www.mdpi.com/journal/diagnostics/special_issues/6J6D0A7U23

ATTIVITA' PROGETTUALI

Progetto	Ruolo prognostico e predittivo dei livelli di frequenza allelica della mutazione di KRAS in pazienti affetti da tumore polmonare non a piccole cellule in trattamento con immunoterapia o terapia mirata (Studio RASLUNG) P.I.: Prof. A. Ardizzoni Ruolo: 1° autore Contributo fondazione CARISBO
Progetto	Analisi di variazioni di sottopopolazioni leucocitarie e di citochine indotte dall'assunzione di steroidi in corso di immunoterapia per il tumore del polmone non a piccole cellule avanzato (Studio IMMUNOSTEROID) P.I.: Prof. A. Ardizzoni Ruolo: 1° autore Fondi ricerca corrente: RC22000564
Progetto	Studio di marcatori circolanti e molecolari funzionalmente coinvolti nei processi di cachessia,

Curriculum vitae

anoressia e sarcopenia in pazienti affetti da non-small cell lung cancer (NSCLC) in fase avanzata (Studio SARCLUNG).

P.I.: Prof. A. Ardizzoni Ruolo: 1° autore

Fondi ricerca corrente: RC22000562

Progetto Valori sierici di procalcitonina nel paziente oncologico con malattia avanzata e sua associazione con l'andamento della malattia neoplastica in tre coorti di pazienti: SCLC, NSCLC e tumori del tratto gastroenterico

P.I.: Prof. A. Ardizzoni Ruolo: collaboratore

Fondi ricerca corrente: RC22000504

Progetto AIPATH: Pathomics for the prediction of immunotherapy outcomes in advanced NSCLC

PI: Prof. B. Besse, Institut Gustave Roussy Ruolo: collaboratore

Progetto SMILE: Study of clinical and biological characteristics associated with Osimertinib outcomes upfront and in following lines in EGFR positive NSCLC patients Ruolo: collaboratore

P.I.: Prof. B. Besse, Institut Gustave Roussy Ruolo: collaboratore

Progetto Monitoraggio in biopsia liquida di pazienti affetti da carcinoma polmonare non a piccole cellule BRAF-V600E mutato trattati con dabrafenib+trametinib: studio prospettico osservazionale multicentrico LIBRA-GOIRC-03-2020

P.I.: Prof. Marcello Tiseo, Azienda Ospedaliero-Universitaria, Parma Ruolo: collaboratore

Progetto Activity of Osimertinib in patients with NSCLC harboring uncommon EGFR mutations: retrospective observational multicenter study (ARTICUNO)

P.I.: Dott. G. Cerea, Azienda ospedaliera Niguarda Ca' Granda Ruolo: collaboratore

Progetto Valutazione mediante test onco-geriatrico G8 del paziente anziano affetto da patologia neoplastica in fase avanzata candidato a ricevere un trattamento innovativo (ONC-OLD)

PI: Dott. Andrea De Giglio Ruolo: 1° autore, PI

Protocollo osservazionale prospettico, multicentrico, nell'ambito del progetto PNRR PE06 - HEAL ITALIA

Partecipazione a trial clinici con ruolo di PI o sub-investigatore

Sub-investigatore PAPHON: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer

Sub-investigatore AMGEN EXP.ACCESS: A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib (AMG 510) for the Treatment of Subjects in Select European Countries with Previously Treated Locally Advanced and Unresectable or Metastatic Non-small Cell Lung Cancer with KRAS p.G12C Mutation

Sub-investigatore ACT16849 Sanofi: A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with lung cancer or pleural mesothelioma

Sub-investigatore Caterpillar 61186372LUC4002: Real-world contemporary systemic anti-cancer therapy effectiveness in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor Ex20ins (i.e. external control cohort); adjusted comparison between real-world outcomes in the external control cohort and amivantamab outcomes in the CHRYSALIS trial CATERPILLAR-RWE

Curriculum vitae

- Sub-investigatore** LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Sub-investigatore** GO41892 (Contact 01): A phase III, multicenter, randomized, open-label, controlled study to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib versus docetaxel monotherapy in patients with metastatic non small cell lung cancer previously treated with an anti pd-1/pd-1 antibody and platinum-containing chemotherapy
- Sub-investigatore** DS1062-A-U301: clinical study protocol phase 3 randomized study of ds-1062a versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations (tropion-lung01)
- Sub-investigatore** Chemo-Immuno (C-I) REAL: An observational study on clinical outcomes of non-squamous NSCLC patients treated with firstline combination of chemo-immunotherapy in clinical practice
- Sub-investigatore** DS1062-A-U202: Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Kinase Inhibitor Therapy and Platinum-based Chemotherapy (TROPION-Lung05)
- Sub-investigatore** PALOMA 3: Clinical Protocol A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
- Sub-investigatore** BO42592: A phase II, randomized, double-blind, placebo-controlled study of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin versus pembrolizumab plus pemetrexed and carboplatin/cisplatin in patients with previously untreated advanced non-squamous non-small-cell lung cancer
- Sub-investigatore** A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
- Sub-investigatore** SPARTA: Phase ½ multicenter study of the safety, pharmacokinetics, and preliminary efficacy of APL-101 in subjects with non-small cell lung cancer with c-MET EXON 14 skip mutation and c-MET dysregulation advanced solid tumors

Relatore a congressi e convegni

- Conferenza** Convegno regionale AIOM Umbria
10/09/2018, Spoleto
Relazione dal titolo 'Dieta e Cancro'
- Conferenza** AIOM - I mercoledì dell'oncologia Endocrinologia oncologica o oncologia endocrina? Questo è il problema I parte
01/12/2021, Webinar
Relazione: 'Rassegna casi clinici: quando la collaborazione oncologo/endocrinologo fa la differenza'
- Conferenza** Thoracic Cancer Trials: Investigator Meeting GOIRC
22/04/2022, Bologna
Moderatore
- Conferenza** La gestione efficace del paziente con stadio III NSCLC non operabile – INTENTO
25/06/2021, Webinar/FAD

Curriculum vitae

Membro di gruppi di ricerca nazionali ed internazionali

European Society of Medical Oncology (**ESMO**)
ID 405203

Associazione Italiana di Oncologia Medica (**AIOM**)

International association for the study of Lung Cancer (**IASLC**)

European Organisation for Research and Treatment (**EORTC**)
Membro dei gruppi di lavoro: Lung Cancer Group

Italian collaborative group for Thymic Malignancies (**TYME**)
Referente oncologo medico per l'IRCCS AOU di Bologna

Attività in campo clinico in Oncologia Medica

Attività oncologica specialistica di Day Hospital, ambulatoriale e di degenza in convenzione con l'IRCCS AOU di Bologna.

Membro del gruppo multidisciplinare aziendale PDTA di patologia oncologica toracica.

Attività didattica

Docente nell'ambito del Master in Clinical Study Coordinator dell'Università di Bologna (a.a. 2022/2023)
Lezione: Ricerca clinica e traslazionale con immune-checkpoint inhibitors

Docente nell'ambito di dottorato di ricerca nazionale in "Medicina di precisione", ciclo XXXIX, A.A. 2023/2024 -Sede UNIPA

Docente per il modulo Oncologia e Cure Palliative (MED 06) per il corso di laurea in Infermieristica-Sede di Faenza, Università di Bologna , A.A. 2023/2024

Supporto e collaborazione per attività didattica presso la Scuola di Specializzazione di Oncologia Medica e scuola di Medicina e Chirurgia dell'Università di Bologna (supporto lezioni frontali, supporto attività tutoraggio clinico a studenti di Medicina e Chirurgia, supporto per attività di tesi).

Appartenenza ad altri gruppi/associazioni

Associazione Specializzandi dell'Università di Perugia (ASUP)
Ruolo: Presidente
01/04/2016 - 01/09/2019

Federspecializzandi
01/03/2019-31/10/2020

Curriculum vitae

Dichiaro di fornire il consenso al trattamento dei propri dati personali (nel rispetto del D. Lgs 196/2003 per le parti ancora valide in quanto non in contrasto con il regolamento U.E. 2016/679)

Bologna, 25/07/2023